Brokerages forecast that Aileron Therapeutics Inc (NASDAQ:ALRN) will announce ($0.58) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Zero analysts have issued estimates for Aileron Therapeutics’ earnings, with estimates ranging from ($0.65) to ($0.49). Aileron Therapeutics reported earnings of ($0.43) per share in the same quarter last year, which suggests a negative year over year growth rate of 34.9%. The firm is scheduled to announce its next earnings report on Thursday, November 8th.
On average, analysts expect that Aileron Therapeutics will report full year earnings of ($2.42) per share for the current financial year, with EPS estimates ranging from ($2.47) to ($2.37). For the next year, analysts expect that the business will report earnings of ($2.15) per share, with EPS estimates ranging from ($2.71) to ($1.63). Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that that provide coverage for Aileron Therapeutics.
Aileron Therapeutics (NASDAQ:ALRN) last announced its quarterly earnings data on Tuesday, August 7th. The company reported ($0.56) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.52) by ($0.04).
In other Aileron Therapeutics news, major shareholder Bioventures Ltd Novartis sold 8,458 shares of the stock in a transaction that occurred on Monday, July 30th. The shares were sold at an average price of $3.35, for a total value of $28,334.30. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold 129,798 shares of company stock valued at $409,889 in the last ninety days. 16.10% of the stock is owned by corporate insiders.
A hedge fund recently raised its stake in Aileron Therapeutics stock. Millennium Management LLC raised its position in Aileron Therapeutics Inc (NASDAQ:ALRN) by 565.4% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 123,658 shares of the company’s stock after acquiring an additional 105,073 shares during the quarter. Millennium Management LLC owned 0.84% of Aileron Therapeutics worth $670,000 at the end of the most recent quarter. 5.94% of the stock is currently owned by institutional investors and hedge funds.
ALRN traded down $0.01 on Friday, reaching $2.38. 87 shares of the company’s stock were exchanged, compared to its average volume of 72,120. The company has a market cap of $37.73 million, a PE ratio of -1.38 and a beta of -0.64. Aileron Therapeutics has a twelve month low of $1.98 and a twelve month high of $14.15. The company has a debt-to-equity ratio of 0.10, a quick ratio of 5.85 and a current ratio of 5.85.
About Aileron Therapeutics
Aileron Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside.
Read More: Understanding Relative Strength Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aileron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aileron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.